Guhan Pharmaceutical Group Co., Ltd.
Shenzhen Stock ExchangeTotal Valuation
Guhan Pharmaceutical Group Co., Ltd. carries a market capitalization of 2.04B, placing it among publicly traded companies globally. Its enterprise value stands at 2.48B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 2.04B |
| Enterprise Value | 2.48B |
Share Statistics
Guhan Pharmaceutical Group Co., Ltd. currently has 239.47M shares outstanding.
| Shares Outstanding | 239.47M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 7.56, and the price-to-book ratio stands at 41.92.
| PE Ratio | N/A |
| PS Ratio | 7.56 |
| PB Ratio | 41.92 |
| P/TBV Ratio | 5.78 |
| P/FCF Ratio | 49.13 |
| P/OCF Ratio | N/A |
Enterprise Valuation
| EV / Sales | 7.32 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | 44.38 |
Financial Position
Guhan Pharmaceutical Group Co., Ltd. maintains a current ratio of 2.12, meaning it holds 2.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 22.97, indicating elevated leverage, while an interest coverage ratio of -6.84 demonstrates limited ability to service its debt obligations.
| Current Ratio | 2.12 |
| Quick Ratio | 0.93 |
| Debt / Equity | 22.97 |
| Debt / EBITDA | -5.37 |
| Interest Coverage | -6.84 |
Financial Efficiency
| Return on Equity (ROE) | -98.77 |
| Return on Assets (ROA) | -11.16 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | 145.40 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 1.33 |
Taxes
Over the trailing twelve months, Guhan Pharmaceutical Group Co., Ltd. has paid 4.78M in income taxes, reflecting an effective tax rate of 540.04.
| Income Tax | 4.78M |
| Effective Tax Rate | 540.04 |
Stock Price Statistics
Guhan Pharmaceutical Group Co., Ltd.'s stock has declined approximately -26.02263% over the past 52 weeks. The 50-day moving average sits at 9.99, while the 200-day moving average is 11.24.
| Beta (5Y) | N/A |
| 52-Week Price Change | -26.02263% |
| 50-Day Moving Average | 9.99 |
| 200-Day Moving Average | 11.24 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Guhan Pharmaceutical Group Co., Ltd. generated 338.99M in revenue and converted that into -119.25M in net income, yielding earnings per share of -0.51. EBITDA reached -24.96M, while operating income came in at -24.96M.
| Revenue | 338.99M |
| Gross Profit | 155.29M |
| Operating Income | -24.96M |
| Pretax Income | -116.43M |
| Net Income | -119.25M |
| EBITDA | -24.96M |
| EBIT | -24.96M |
| Earnings Per Share (EPS) | -0.51 |
Balance Sheet
Guhan Pharmaceutical Group Co., Ltd. holds 216.54M in cash and equivalents against 134.12M in total debt, resulting in a net debt position of -91.49M. Total book value stands at 61.11M, with working capital of 261.22M providing operational flexibility.
| Cash & Cash Equivalents | 216.54M |
| Total Debt | 134.12M |
| Net Debt | -91.49M |
| Equity (Book Value) | 61.11M |
| Book Value Per Share | 0.26 |
| Working Capital | 261.22M |
Cash Flow
After subtracting -52.14M in capital expenditures, free cash flow totaled -52.14M - equivalent to -0.22 per share.
| Operating Cash Flow | N/A |
| Capital Expenditures | -52.14M |
| Free Cash Flow | -52.14M |
| FCF Per Share | -0.22 |
Margins
Guhan Pharmaceutical Group Co., Ltd. operates with a gross margin of 45.81, reflecting its pricing power and cost economics. The operating margin of -7.36 and net profit margin of -35.18 provide insight into operational efficiency.
| Gross Margin | 45.81 |
| Operating Margin | -7.36 |
| Pretax Margin | -34.35 |
| Profit Margin | -35.18 |
| EBITDA Margin | -7.36 |
Dividends & Yields
The company's payout ratio of -2.81 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 0.01 |
| Dividend Yield | N/A |
| Payout Ratio | -2.81 |
| Shareholder Yield | -1.54 |
| FCF Yield | 2.04 |
Stock Splits
Guhan Pharmaceutical Group Co., Ltd.'s most recent stock split took place on September 4, 2012 with a 10:11 split ratio.
| Last Split Date | 9/4/2012 |
| Split Ratio | 10:11 |
Scores
Guhan Pharmaceutical Group Co., Ltd. posts an Altman Z-Score of 3.98, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 3.98 |